Covidien's ablation system gets US nod for liver tumours
This article was originally published in Clinica
The Evident microwave ablation system developed by Covidien has received US 510(k) clearance for use in the ablation of nonresectable liver tumours. The Evident technology can be used to coagulate soft tissue during percutaneous, laparoscopic and open surgical procedures in patients who cannot otherwise be treated surgically. As the system uses microwave ablation, there is no current flow through the patient, eliminating the need for grounding pads, the Boulder, Colorado firm said. Covidien claims that the Evident permits ablation procedures to be performed up to 60% faster than is possible with other ablation products, with ablations being achieved "in approximately 10 minutes".
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.